U.S. markets closed
  • S&P 500

    -23.89 (-0.54%)
  • Dow 30

    -149.06 (-0.42%)
  • Nasdaq

    -105.59 (-0.71%)
  • Russell 2000

    -13.78 (-0.62%)
  • Crude Oil

    +0.19 (+0.26%)
  • Gold

    -18.70 (-1.02%)
  • Silver

    -0.23 (-0.90%)

    -0.0025 (-0.21%)
  • 10-Yr Bond

    -0.0300 (-2.36%)

    -0.0051 (-0.37%)

    +0.1540 (+0.14%)

    +1,823.82 (+4.61%)
  • CMC Crypto 200

    +5.13 (+0.54%)
  • FTSE 100

    -46.12 (-0.65%)
  • Nikkei 225

    -498.83 (-1.80%)

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

·4 min read

Clinical-stage company, Prothena Corporation PRTA, reported disappointing results for the third quarter of 2020.

The company reported a loss of 77 cents per share, wider than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago quarter’s loss of 49 cents.

Revenues mainly came from the company’s collaboration with Roche Holdings RHHBY. Quarterly revenues came in at $0.16 million, missing the Zacks Consensus Estimate by 70.54%. Revenues were down from $0.2 million in the year-ago quarter.

The company’s shares have lost 12% in the past year compared with the industry’s decline of 6.4%.


Quarter in Detail

R&D expenses were $21.6 million, up from $12.5 million in the year-ago quarter due to higher manufacturing costs, increased collaboration expenses with Roche related to the prasinezumab program and elevated R&D consulting expenses.

General and administrative (G&A) expenses came in at $9.4 million, up from $8.7 million in the year-ago quarter.

As of Sep 30, 2020, Prothena had $317.2 million in cash, cash equivalents and restricted cash.

Pipeline Updates

The company is evaluating prasinezumab in collaboration with Roche for the treatment of Parkinson’s disease.

Roche recently presented results from the phase II PASADENA study of prasinezumab in patients with early Parkinson’s disease. Results showed that prasinezumab significantly reduced decline in motor function by 35% (pooled dose levels) versus placebo after one year of treatment on the centrally rated assessment of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, a clinical examination of motor function. Additionally, prasinezumab-treated patients demonstrated a significant delay in time to clinically meaningful worsening of motor progression on the site rated assessment of time to at least a 5-point progression on MDS-UPDRS Part III compared to placebo over one year, with a hazard ratio of 0.82.

The companies will advance prasinezumab into a phase IIb study in patients with early Parkinson’s disease. The study will be designed to further assess the efficacy of prasinezumab by expanding the patient population enrolled in PASADENA to include patients with early Parkinson’s disease on stable levodopa therapy.

Prothena expects to report new data in the fourth quarter of this year from the dose-escalation and available LTE portion of the study on PRX004, a potential treatment for ATTR amyloidosis.

Meanwhile, the company is advancing an early-stage pipeline of programs for a number of potential neurological indications. Prothena expects to advance IND-enabling activities in 2020 for PRX005, its preclinical tau program, part of a global neuroscience collaboration with Bristol-Myers Squibb BMY, and expects to file an IND in 2021.

Prothena has initiated IND-enabling studies for PRX012, its preclinical Aβ program, and expects to file an IND in 2021.

Zacks Rank & A Stock to Consider

Prothena currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Zoetis ZTS, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zoetis’ earnings estimates have increased 29 cents for 2020 in the past 90 days.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Zoetis Inc. (ZTS) : Free Stock Analysis Report
Prothena Corporation plc (PRTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research